Nanogen receives six diabetes patents

Nanogen today announced that they have been provided with six different patents by the Patent and Trademark Office in America. The patents have been awarded for inventions related to diabetes and Alzheimer’s disease, with a focus on the use of biomarkers.
The patents include the following:
U.S. Patent No. 7,052, 849, “Protein biopolymer markers predictive of insulin resistance,”
U.S. Patent No. 7, 049,397, “Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons,”
U.S. Patent No. 7,087,435, “Biopolymer marker indicative of disease state having a molecular weight of 2735 daltons,”
The patents may be useful in early diagnosis and detection of metabolic syndromen, also known as syndrome x or pre-diabetes. Sydrome X is often characterised by resistance to insulin, abnormal blood lipids, triglycerides and high blood pressure. This can then develop into diabetes and its resultant complications.
Further patents were granted relating to Alzheimer’s disease and syndrome X. Nanogen may have a strong role to play in the future of early diagnosis, awareness and therefore prevention.